10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

# Anti-FZD7 Reference Antibody (U.Toronto patent anti-FZD7)

Recombinant Antibody
Catalog # APR10914

## Product Information

| | |
|---|---|
| **Application** | Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA |
| **Primary Accession** | O75084 |
| **Reactivity** | Human |
| **Clonality** | Monoclonal |
| **Isotype** | IgG1 |
| **Calculated MW** | 63620 |

## Additional Information


| | |
|---|---|
| **Target/Specificity** | FZD7 |
| **Endotoxin Conjugation** | Unconjugated |
| **Expression system** | CHO |
| **Format** | Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column. |

## Protein Information


| | |
|---|---|
| **Name** | FZD7 |
| **Function** | Receptor for Wnt proteins. Most frizzled receptors are coupled to the beta-catenin canonical signaling pathway, which leads to the activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin and activation of Wnt target genes. A second signaling pathway involving PKC and calcium fluxes has been seen for some family members, but it is not yet clear if it represents a distinct pathway or if it can be integrated in the canonical pathway, as PKC seems to be required for Wnt-mediated inactivation of GSK-3 kinase. Both pathways seem to involve interactions with G proteins. Activation by WNT8 induces expression of beta-catenin target genes (By similarity). Following ligand activation, binds to CCDC88C/DAPLE which displaces DVL1 from FZD7 and leads to inhibition of canonical Wnt signaling, activation of G proteins by CCDC88C and triggering of non-canonical Wnt responses (PubMed:26126266). May be involved in transduction and intercellular transmission of polarity information during tissue morphogenesis and/or in differentiated tissues. |
| **Cellular Location** | Cell membrane; Multi-pass membrane protein. Endosome membrane; |

| | |
|---|---|
| | Multi-pass membrane protein. Note=Associated to the plasma membrane in the presence of FZD7 and phosphatidylinositol 4,5-bisphosphate (PIP2). Localized in recycling endosomes in other conditions |
| **Tissue Location** | High expression in adult skeletal muscle and fetal kidney, followed by fetal lung, adult heart, brain, and placenta Specifically expressed in squamous cell esophageal carcinomas |

## Images




Anti-FZD7 Reference Antibody (U.Toronto patent anti-FZD7) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 90%.



The purity of Anti-FZD7 Reference Antibody (U.Toronto patent anti-FZD7) is more than 95%, determined by SEC-HPLC.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.